When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Humacyte (HUMA) announced the pricing of an underwritten public offering of 47.62M shares of its common stock at a public offering price of $1.05 per share. The gross proceeds from the offering are ...

Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston –– Women ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has ...

Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity ...

Thank you, Tom and good morning, everyone and thank you for joining us for our first quarter 2025 financial results and ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $5.17, marking a -1.34% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow saw an ...

Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered ...

Stock market movers today: futures rebound after AI sell-off as oil dips; see top gainers/losers like Navan, Oracle, Humacyte ...

Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access June 15, 2026 5:00 PM EDTCompany ...

On June 10, 2026, Humacyte reported positive top-line interim results from its Phase 3 V012 trial evaluating its acellular tissue engineered vessel (ATEV) for dialysis access in female patients with ...